D

Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192

Watchlist Manager
Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192
Watchlist
Price: 45.1 CNY -3.34% Market Closed
Market Cap: 18.7B CNY
Have any thoughts about
Dizal Jiangsu Pharmaceutical Co Ltd?
Write Note

Dizal Jiangsu Pharmaceutical Co Ltd
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Dizal Jiangsu Pharmaceutical Co Ltd
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
D
Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192
Cash & Cash Equivalents
ÂĄ69.5m
CAGR 3-Years
-49%
CAGR 5-Years
18%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Cash & Cash Equivalents
ÂĄ15B
CAGR 3-Years
33%
CAGR 5-Years
32%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Cash & Cash Equivalents
ÂĄ3.8B
CAGR 3-Years
75%
CAGR 5-Years
55%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Cash & Cash Equivalents
ÂĄ1.9B
CAGR 3-Years
-1%
CAGR 5-Years
13%
CAGR 10-Years
7%
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Cash & Cash Equivalents
ÂĄ5.6B
CAGR 3-Years
3%
CAGR 5-Years
82%
CAGR 10-Years
19%
Imeik Technology Development Co Ltd
SZSE:300896
Cash & Cash Equivalents
ÂĄ2.4B
CAGR 3-Years
-11%
CAGR 5-Years
56%
CAGR 10-Years
N/A
No Stocks Found

Dizal Jiangsu Pharmaceutical Co Ltd
Glance View

Market Cap
18.4B CNY
Industry
Biotechnology

Dizal (Jiangsu) Pharmaceutical Co., Ltd. engages in the discovery, development, and commercialization of innovative medicines. The company is headquartered in Shanghai, Shanghai and currently employs 328 full-time employees. The company went IPO on 2021-12-10. The firm focuses on diseases such as malignant tumors and immune diseases. The main candidate innovative drugs in the Company's research and development (R&D) pipeline are DZD4205, DZD9008, DZD1516, DZD2269, DZD8586, DZD0095. The firm is still in the R&D stage.

Intrinsic Value
30.31 CNY
Overvaluation 33%
Intrinsic Value
Price
D

See Also

What is Dizal Jiangsu Pharmaceutical Co Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
69.5m CNY

Based on the financial report for Dec 31, 2023, Dizal Jiangsu Pharmaceutical Co Ltd's Cash & Cash Equivalents amounts to 69.5m CNY.

What is Dizal Jiangsu Pharmaceutical Co Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
18%

Over the last year, the Cash & Cash Equivalents growth was -43%. The average annual Cash & Cash Equivalents growth rates for Dizal Jiangsu Pharmaceutical Co Ltd have been -49% over the past three years , 18% over the past five years .

Back to Top